Company Overview
About Isabl
Isabl is a New York-based whole-genome and transcriptome cancer diagnostics company — backed by Y Combinator (W20) with $5 million in total funding including $3 million from Two Sigma Ventures, BoxOne Ventures, Bossa Invest, and Jude Gomilla, plus a $2 million SBIR grant from the National Cancer Institute (NCI) — commercializing the Isabl GxT (Genome x Transcriptome) diagnostic platform that received FDA Breakthrough Device Designation for comprehensive tumor profiling that analyzes entire tumor genomes and transcriptomes simultaneously to identify cancer-associated mutations, fusion genes, and expression patterns that guide treatment selection. Founded in 2020 after incubating at Memorial Sloan Kettering Cancer Center (MSKCC) from 2015-2019, Isabl's genomic testing platform is specifically advancing through March 2025 NCI funding for pediatric and rare solid cancers where comprehensive genomic profiling can identify targeted therapy opportunities that standard panel tests miss.
Business Model & Competitive Advantage
Isabl's whole-genome and transcriptome sequencing approach (WGS + WTS) generates more complete tumor genomic information than the targeted gene panel tests (which analyze 50-500 genes) that currently dominate clinical genomic oncology testing: WGS captures all 3 billion base pairs of the tumor genome (detecting structural variants, copy number alterations, mutational signatures, and tumor mutational burden) while WTS captures gene expression across all 20,000+ human genes (identifying fusion transcripts, expression-level changes in cancer driver pathways, and RNA-level splicing variants that DNA sequencing alone misses). The FDA Breakthrough Device Designation (granted for rare and pediatric cancers where comprehensive profiling is most needed) provides the regulatory framework for accelerated FDA review of the Isabl GxT platform as a companion diagnostic. The MSK Cancer Center incubation (one of the world's leading cancer research and treatment institutions) provides the clinical validation context that oncology diagnostic company formation requires.
Competitive Landscape 2025–2026
In 2025, Isabl competes in the cancer genomics diagnostics, comprehensive genomic profiling, and precision oncology market with Foundation Medicine (FDA-approved CGP tests, Roche subsidiary), Tempus AI (NASDAQ: TEM, AI-enabled precision medicine, $1.1B IPO 2024), and Guardant Health (NASDAQ: GH, liquid biopsy and CGP, $1.9B raised) for oncology tumor profiling and comprehensive genomic testing adoption. The NCI SBIR grant (competitive federal funding awarded to early-stage biomedical companies for high-priority cancer research) validates Isabl's scientific approach and provides non-dilutive capital for the pediatric oncology program development. Two Sigma Ventures' investment (quantitative finance and data science firm with deep computational biology conviction) reflects the machine learning integration in Isabl's genomic data analysis pipeline. The 2025 strategy focuses on clinical validation studies for the Isabl GxT in pediatric solid tumors, expanding the NCI partnership for rare cancer genomic profiling programs, and building the clinical laboratory infrastructure for CLIA-certified commercial testing.
Recent Activity
View all →Material Event filed 2026-09-25
Material Event filed 2026-09-10
Material Event filed 2026-08-12
Quarterly Report filed 2026-07-31
Material Event filed 2026-07-28
Material Event filed 2026-07-13
Key Differentiators
Emerging Innovator
Isabl is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
S2
S2 is an AI-powered security platform focused on vulnerability discovery and attack surface management for enterprise security teams. The company's platform combines automated scanning, AI-powered ana
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
Epic Systems
Epic Systems Corporation was founded in 1979 by Judith Faulkner and is headquartered in Verona, Wisconsin, remaining privately held with Faulkner as majority owner. The company develops large-scale el
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Compare Isabl with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Isabl? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Isabl Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Isabl vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →